For the three months ended Sept. 30, the firm said that total revenues fell to $1.2 million from $1.3 in the year-ago quarter with OVA1 volumes essentially flat.
The firm said that overall cartridge volumes in Q3 were back at pre-pandemic levels, and that it is on track to achieve targeted 30 percent growth for full-year 2020.
A negative preliminary decision regarding reimbursement for the company's flagship colon cancer screening test in the US remains an issue for the company.
Development revenues for the Seattle-based firm ticked up 5 percent to $15.0 million in Q3, partially offset by a 3 percent dip in sequencing revenues.